Imagion Biosystems Ltd
Imagion Biosystems Limited is a medical imaging company.
The business
Imagion Biosystems Limited is a medical imaging company. The Company is developing a non-radioactive and precision diagnostic molecular imaging technology. Its principal activity consists of nanotechnology, biotechnology, cancer diagnostics and medical imaging using magnetic resonance. It uses bio-safe magnetic nanoparticles to detect cancer and other diseases. The Company operates through Research and Development segment. Its MagSense HER2 Imaging Agent (MSH2IA) is a first-in-class molecular imaging product candidate that is intended to detect tumors more accurately than relying solely on anatomical abnormalities seen in conventional imaging. With its tumor targeting, MSH2IA produces Magnetic resonance imaging (MRI) images that are differentiable between an abnormal lymph node and a normal node in HER2 positive breast cancer patients undergoing axillary imaging. Its PrecisionMRX products include Dextran-Coated, mPEG Coated, Oleic Acid Coated and Carboxylic Acid Functionalized.
Small Caps Research
No research on Imagion Biosystems Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise IBX based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Imagion Biosystems Considers Lower Dosage Of Magsense Breast Cancer Imaging Agent For Phase 2 Trial
Imagion Biosystems (ASX: IBX) has received positive results on dosage tests in preparation for a Phase 2 clinical trial of HER2 breast cancer imaging agent MagSense.
Imagion Biosystems Starts Manufacture of MagSense Imaging Agent for Phase 2 HER2 Breast Cancer Trial
Imagion Biosystems (ASX: IBX) has commenced manufacturing of its MagSense imaging agent ahead of a Phase 2 HER2 breast cancer clinical trial to start in the US before year end. The agent will assess axillary nodal disease in patients diagnosed with HER2+ breast cancer and Imagion believes it will be of significant clinical value to […]
Imagion Biosystems Gains FDA Fast-Track Approval for MagSense HER2 Breast Cancer Imaging Agent
Imagion Biosystems (ASX: IBX) has announced it will fast-track a new batch of MagSense HER2 imaging agent ahead of a Phase 2 breast cancer trial this year. The decision follows a meeting with the US Food and Drug Administration where Imagion offered detailed responses on the structure and operation of the planned trial. The agency’s […]
Imagion Biosystems advances MagSense HER2 imaging agent with FDA application
Cancer detection specialist Imagion Biosystems (ASX: IBX) has taken the next step in progressing its MagSense HER2 imaging agent, lodging an application with the US Food and Drug Administration (FDA). The application for initiated manufacturing of MagSense HER2 is an essential requirement for filing an Investigational New Drug (IND) application with the FDA in mid-2025. […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.